Enoxaparin Sodium Injection shortage
To Be Discontinued 24 presentations · 1 manufacturers · first FDA posting Oct 20, 2026 · last update Oct 20, 2026
Manufacturers: Sanofi-Aventis U.S. LLC
Stated reasons (per FDA): Not stated (FDA did not give a reason)
More info: FDA Drug Shortages Database · ASHP drug shortages list (search there for this drug)
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Lovenox, Injection, 40 mg/.4 mL (NDC 0075-0620-40) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 60 mg/.6 mL (NDC 0075-0621-60) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 80 mg/.8 mL (NDC 0075-0622-80) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 100 mg/1 mL (NDC 0075-0623-00) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 30 mg/.3 mL (NDC 0075-0624-30) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 300 mg/3 mL (NDC 0075-0626-03) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 120 mg/.8 mL (NDC 0075-2912-01) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 150 mg/1 mL (NDC 0075-2915-01) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 30 mg/.3 mL (NDC 0075-8013-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 40 mg/.4 mL (NDC 0075-8014-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 60 mg/.6 mL (NDC 0075-8016-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 80 mg/.8 mL (NDC 0075-8018-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 100 mg/1 mL (NDC 0075-8020-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 120 mg/.8 mL (NDC 0075-8022-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 150 mg/1 mL (NDC 0075-8025-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Lovenox, Injection, 300 mg/3 mL (NDC 0075-8030-01) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Enoxaparin Sodium, Injection, 30 mg/.3 mL (NDC 0955-1003-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Enoxaparin Sodium, Injection, 40 mg/.4 mL (NDC 0955-1004-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Enoxaparin Sodium, Injection, 60 mg/.6 mL (NDC 0955-1006-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Enoxaparin Sodium, Injection, 80 mg/.8 mL (NDC 0955-1008-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Enoxaparin Sodium, Injection, 100 mg/1 mL (NDC 0955-1010-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Enoxaparin Sodium, Injection, 120 mg/.8 mL (NDC 0955-1012-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Enoxaparin Sodium, Injection, 150 mg/1 mL (NDC 0955-1015-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |
| Enoxaparin Sodium, Injection, 300 mg/3 mL (NDC 0955-1016-01) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029. | Posted Oct 20, 2026 Updated Oct 20, 2026 Discontinued Oct 20, 2026 |